Results 221 to 230 of about 284,370 (314)

Data‐Independent Acquisition Mass Spectrometry in Tumor Classification and Cancer Biomarker Research

Mass Spectrometry Reviews, EarlyView.
Abstract Cancer treatment is far from optimal also because current classification systems do not reflect the complex molecular status of the tumor and its phenotype in sufficient detail. To construct molecular tumor classifiers, omics tools provide complex molecular data reflecting many aspects from genotype to phenotype.
Jan Simonik, Petr Lapcik, Pavla Bouchalova, Pavel Bouchal   +3 more
wiley   +1 more source

Real-World Safety and Efficacy of Biosimilar Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer: A Prospective Single-Institution Study From India. [PDF]

Int J Breast Cancer
Gandrala D, Rajappa SJ, Mallavarapu K, Santa A, Pavan Kumar B, Pinninti R, Ladda PS, Pathi N, Kandem S, Tewani RK, Thummar V, Mehta P.   +11 more
europepmc   +1 more source

Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer. [PDF]

NPJ Precis Oncol
Tarantino P, Kim SE, Hughes ME, Kusmick RJ, Smith K, Brasó-Maristany F, Nyein Chan NN, Paré Brunet L, Alder L, Garcia-Cortes D, Gomez Tejeda Zanudo J, Pereslete AM, Noteware L, Moore H, Van Swearingen AED, Li T, Gupta H, D'Amico O, Martini A, Morganti S, Spindel J, Cook C, McLaughlin C, Dvir K, Garrido-Castro AC, Sammons S, Files J, Sendrick K, Buck S, Dillon D, Jeselsohn R, Li YY, Cherniack AD, LoRusso P, Lustberg M, Vega-León R, Pardo F, Davis J, Mueller C, Corgiat B, Curigliano G, Anders CK, Petricoin EF, Rimm DL, Prat A, Tayob N, Lin NU, Tolaney SM.   +47 more
europepmc   +1 more source

Topological analysis of the human lymph node reticular network predicts outcome in breast cancer

The Journal of Pathology, EarlyView.
Abstract Axillary LNs (ALNs) initiate immune responses in breast cancer (BC) but how and when ALNs become dysfunctional, facilitating metastasis, is unclear. The fibroblastic reticular cell (FRC) network within ALNs provides structural support and mediates immune homeostasis, but we have yet to elucidate whether this network changes during BC ...
Amy M Llewellyn, Sharon L D'Costa, Cheun YR Lam, Jasmine A Gore, Veronika Lachina, Daniel J Shewring, Sophie E Acton, Kalnisha Naidoo   +7 more
wiley   +1 more source

Metabolic engineering of SLC38A2 reprograms glutamine utilization and enhances CAR-macrophage antitumor function in solid tumors. [PDF]

Cancer Biol Med
Liu M, Chen Q, Zhang L, Zhou Y, Wen N, Jin J, Cai J, Su S, Li J, Zhao Q.   +9 more
europepmc   +1 more source

Image Analysis Platform for Comprehensive Quantification of Extracellular Vesicle Morphology

PROTEOMICS, EarlyView.
ABSTRACT Extracellular vesicles (EVs) are membrane‐encapsulated nanoparticles with key roles in cell biology and growing importance in biomedicine. However, EVs are challenging to characterize because they are highly heterogeneous. Single EV analysis methods are valuable tools for addressing this challenge.
Alexander Spark, Nan Jiang, Benjamin Purnell, Mihajlo Radmilovic, Andras Saftics, Eugenia Romano, Tijana Jovanovic‐Talisman, Alexandre Kitching   +7 more
wiley   +1 more source

Overcoming Trastuzumab-Pertuzumab Resistance and Optimizing Sequential Anti-HER2 Therapy in HER2-Positive Metastatic Breast Cancer. [PDF]

Cancers (Basel)
Yamamoto Y.
europepmc   +1 more source

Proteomic Characterization of AS1411 Reveals ATP6AP1 as a Mediator of Triple‐Negative Breast Cancer Progression

PROTEOMICS, EarlyView.
ABSTRACT Triple‐negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by high metastatic potential, poor prognosis, and limited effective therapeutic options. In this study, we investigated the molecular mechanisms underlying the anticancer effects of the nucleolin (NCL)‐targeting DNA aptamer AS1411 using label‐free ...
Ha‐Song Bae, Yun‐Jeong Seo, Eun‐Bi Kim, Hyoung‐Min Park, I‐Hsuan Liu, J. Eugene Lee, Jae‐Young Kim   +6 more
wiley   +1 more source

Risk of CNS relapse following pathological complete response to neoadjuvant chemotherapy in early breast cancer. [PDF]

Breast Cancer Res Treat
de Moura Leite L, de Almeida GR, Tavares MC, Cesca MG, Campos FAB, de Oliveira FA, Dornellas DMS, Saldanha EF, Guimarães PT, de Arruda DDS, de Held MFSD, Viana RL, Moura FGR, Loose SK, Silva SF, Pirolli R, Fogassa CAZ, Mattos BRS, Sanches SM, de Lima VCC.   +19 more
europepmc   +1 more source

Intelligent nano‐platforms in breast cancer therapy: Current advances and future perspectives

Precision Medical Sciences, EarlyView.
The smart nano platform in breast cancer treatment is designed with advanced nanocarriers, including liposomes, hydrogels, porous nanoparticles, and aptamer‐based systems. These systems are capable of targeted drug release and response to environmental stimuli.
Tina Rahimi, Moluk Aivazi
wiley   +1 more source